Nearing the Unthinkable Scenario of 1 in 2 Children With Autism in the U.S.
The prevalence for autism spectrum disorder (ASD) among eight-year-old children in the United States reached 1 in 36 last year. At least, that’s the rate that was confirmed by an analysis published in the U.S. Centers for Disease Control and Prevention’s (CDC) epidemiological digest Morbidity and Mortality Weekly Report (MMWR) on Mar. 24, 2023. That […]
FDA Licenses Merck’s Capvaxive Pneumococcal Vaccine
On June 17, 2024, the U.S. Food and Drug Administration (FDA) licensed Merck & Company, Inc.’s new pneumococcal conjugate vaccine Capvaxive (formerly V116) for adults 18 years of age and older. The vaccine is designed to protect against 21 types of the bacteria causing pneumococcal disease, which can lead to severe infection in the lungs […]
A New Openness to the Reality of Vaccine Injury?
Normally, when you do a search on Google for “vaccine” of any variant of the word or phrase which includes the word, all you find is articles or websites that proclaim the wonders of vaccines—how these biologic drugs saved humanity from just about everything. You seldom find mention on Google of the downside of these […]
COVID Shots and Rise in Excess Deaths in Many Countries
A recent study published in the British medical journal The BMJ found a total of 3,089,465 “excess deaths” reported in 47 Western countries during the first three years of the COVID-19 pandemic—from Jan. 1, 2020 through Dec. 31, 2022. The study, conducted by researchers from Vrije Universiteit Amsterdam in the Netherlands, suggests that part of the […]
WHO Prequalifies Takeda’s Qdenga Dengue Vaccine
On May 10, 2024, the World Health Organization (WHO) granted prequalification status to the Qdenga (TAK-003) dengue vaccine, developed by Takeda Pharmaceutical Company Ltd. of Tokyo, Japan. The live attenuated virus vaccine is recommended to be given in two doses three months apart to children six to 16 years old living in areas where dengue […]
Autism Treatment Market Set to More Than Double by 2030
As the rates of autism spectrum disorder (ASD) continue rising in the United States and around the world, so does the market for treating the immune and brain dysfunction associated with the neurological and developmental disorder that affects one in 36 eight-year-old children in the U.S., with one in six suffering with a developmental disability. […]
